Polaryx Therapeutics, Inc.(PLYX)
Biotechnology
Rare Disease / Orphan Drug
| Filing Date | Insider | Type | 10b5-1 | Net Shares | Ownership changeShares owned | Avg. Price | Value | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | Yang Alex Keun Mo Chief Executive Officer | Purchase | +88,453 | +0.37%24,233,249 | $4.07 | $360,004 | View SEC filing | |
| 2026-02-20 | Landis G. Michael Chief Financial Officer | Purchase | +2,867 | +800.84%3,225 | $2.79 | $7,991 | View SEC filing |
1-2 of 2